Broad molecular profiling for targeted cancer care

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge.

The InVision® proprietary platform is a tagged-amplicon sequencing (TAm-Seq™) method, which allows amplification and deep sequencing of genomic regions spanning thousands of bases from individual copies of fragmented DNA.

InVision®

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge. InVision is able to amplify a panel of 34 well-known, specially selected, cancer-related genes.

Plasma collection DNA extraction
ctDNA
analysis
Bioinformatics analysis
Oncology report generated

When analyzed with Inivata’s propriety algorithms and database, this can be used to generate a detailed report, providing critical insights into the patient’s tumor profile.

Stand-out sensitivity

InVision® has been developed to provide an exceptional level of sensitivity, while retaining a comprehensive coverage.

>99% of mutations at >0.5% Allele Frequency

Optimized Gene Panel

InVision® ctDNA 34-Gene Molecular Profiling Panel, with Hotspot Regions and Exon Tiling (88-100% gene coverage)

AKT1
ALK
BRAF
CCND1
CDKN2A
CTNNB1
EGFR
ERBB2
ESR1
FGFR2
FGFR3
FOXL2
GATA3
GNA11
GNAQ
GNAS
HRAS
IDH1
IDH2
KIT
KRAS
MED12
MET
MYC
NFE2L2
NRAS
PDGFRA
PIK3CA
PPP2R1A
PTEN
RET
STK11
TP53
U2AF1
Exon Tiling (88-100% gene coverage)
Hotspot regions

This panel of genes was carefully selected to provide highly informative content without compromising on sensitivity and specificity.